Post Marketing Surveillance Study To Observe Safety And Efficacy Of Aromasin In The Patients With Early Or Advanced Breast Cancer
All cases at the participating institutions.
Observational
Observational Model: Case-Only, Time Perspective: Prospective
The nature, incidence, duration, and severity of adverse events; discontinuation due to adverse events; outcome and causality will be monitored in this study.
adjuvant 1 year ; advanced 6 years
Yes
Pfizer CT.gov Call Center
Study Director
Pfizer
Korea: Food and Drug Administration
A5991089
NCT01047358
August 2010
July 2014
Name | Location |
---|